ATC code A10
ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3] Subgroup A10 is part of the anatomical group A Alimentary tract and metabolism.[4]
| ATC codes |
|---|
| A Alimentary tract and metabolism |
| A01 Stomatological preparations |
| A02 Drugs for acid related disorders |
| A03 Drugs for functional gastrointestinal disorders |
| A04 Antiemetics and antinauseants |
| A05 Bile and liver therapy |
| A06 Drugs for constipation |
| A07 Antidiarrheals, intestinal anti-inflammatory/anti-infective agents |
| A08 Antiobesity preparations, excluding diet products |
| A09 Digestives, including enzymes |
| A10 Drugs used in diabetes |
| A11 Vitamins |
| A12 Mineral supplements |
| A13 Tonics |
| A14 Anabolic agents for systemic use |
| A15 Appetite stimulants |
| A16 Other alimentary tract and metabolism products |
|
|
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QA10.[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
A10A Insulins and analogues
A10AB Insulins and analogues for injection, fast-acting
- A10AB01 Insulin (human)
- A10AB02 Insulin (beef)
- A10AB03 Insulin (pork)
- A10AB04 Insulin lispro
- A10AB05 Insulin aspart
- A10AB06 Insulin glulisine
- A10AB30 Combinations
A10AC Insulins and analogues for injection, intermediate-acting
- A10AC01 Insulin (human)
- A10AC02 Insulin (beef)
- A10AC03 Insulin (pork)
- A10AC04 Insulin lispro
- A10AC30 Combinations
A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
- A10AD01 Insulin (human)
- A10AD02 Insulin (beef)
- A10AD03 Insulin (pork)
- A10AD04 Insulin lispro
- A10AD05 Insulin aspart
- A10AD06 Insulin degludec and insulin aspart
- A10AD30 Combinations
A10AE Insulins and analogues for injection, long-acting
- A10AE01 Insulin (human)
- A10AE02 Insulin (beef)
- A10AE03 Insulin (pork)
- A10AE04 Insulin glargine
- A10AE05 Insulin detemir
- A10AE06 Insulin degludec
- A10AE30 Combinations
- A10AE54 Insulin glargine and lixisenatide
- A10AE56 Insulin degludec and liraglutide
A10AF Insulins and analogues for inhalation
- A10AF01 Insulin (human)
A10B Blood glucose lowering drugs, excluding insulins
A10BA Biguanides
- A10BA01 Phenformin
- A10BA02 Metformin
- A10BA03 Buformin
A10BB Sulfonylureas
- A10BB01 Glibenclamide
- A10BB02 Chlorpropamide
- A10BB03 Tolbutamide
- A10BB04 Glibornuride
- A10BB05 Tolazamide
- A10BB06 Carbutamide
- A10BB07 Glipizide
- A10BB08 Gliquidone
- A10BB09 Gliclazide
- A10BB10 Metahexamide
- A10BB11 Glisoxepide
- A10BB12 Glimepiride
- A10BB31 Acetohexamide
A10BC Sulfonamides (heterocyclic)
- A10BC01 Glymidine
A10BD Combinations of oral blood glucose lowering drugs
- A10BD01 Phenformin and sulfonylureas
- A10BD02 Metformin and sulfonylureas
- A10BD03 Metformin and rosiglitazone
- A10BD04 Glimepiride and rosiglitazone
- A10BD05 Metformin and pioglitazone
- A10BD06 Glimepiride and pioglitazone
- A10BD07 Metformin and sitagliptin
- A10BD08 Metformin and vildagliptin
- A10BD09 Pioglitazone and alogliptin
- A10BD10 Metformin and saxagliptin
- A10BD11 Metformin and linagliptin
- A10BD12 Pioglitazone and sitagliptin
- A10BD13 Metformin and alogliptin
- A10BD14 Metformin and repaglinide
- A10BD15 Metformin and dapagliflozin
- A10BD16 Metformin and canagliflozin
- A10BD17 Metformin and acarbose
- A10BD18 Metformin and gemigliptin
- A10BD19 Linagliptin and empagliflozin
- A10BD20 Metformin and empagliflozin
- A10BD21 Saxagliptin and dapagliflozin
- A10BD22 Metformin and evogliptin
- A10BD23 Metformin and ertugliflozin
- A10BD24 Sitagliptin and ertugliflozin
- A10BD25 Metformin, saxagliptin and dapagliflozin
- A10BD26 Metformin and lobeglitazone
- A10BD27 Metformin, linagliptin and empagliflozin
A10BG Thiazolidinediones
- A10BG01 Troglitazone
- A10BG02 Rosiglitazone
- A10BG03 Pioglitazone
- A10BG04 Lobeglitazone
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
- A10BH01 Sitagliptin
- A10BH02 Vildagliptin
- A10BH03 Saxagliptin
- A10BH04 Alogliptin
- A10BH05 Linagliptin
- A10BH06 Gemigliptin
- A10BH07 Evogliptin
- A10BH08 Teneligliptin
- A10BH51 Sitagliptin and simvastatin
- A10BH52 Gemigliptin and rosuvastatin
A10BJ Glucagon-like peptide-1 (GLP-1) analogues
- A10BJ01 Exenatide
- A10BJ02 Liraglutide
- A10BJ03 Lixisenatide
- A10BJ04 Albiglutide
- A10BJ05 Dulaglutide
- A10BJ06 Semaglutide
- A10BJ07 Beinaglutide
A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
- A10BK01 Dapagliflozin
- A10BK02 Canagliflozin
- A10BK03 Empagliflozin
- A10BK04 Ertugliflozin
- A10BK05 Ipragliflozin
- A10BK06 Sotagliflozin
- A10BK07 Luseogliflozin
- QA10BK90 Velagliflozin
A10BX Other blood glucose lowering drugs, excluding insulins
- A10BX01 Guar gum
- A10BX02 Repaglinide
- A10BX03 Nateglinide
- A10BX05 Pramlintide
- A10BX06 Benfluorex
- A10BX08 Mitiglinide
- A10BX15 Imeglimin
References
- "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- "ATC/DDD Index 2022: code A10". WHO Collaborating Centre for Drug Statistics Methodology.
- "ATCvet Index 2022: code QA10". WHO Collaborating Centre for Drug Statistics Methodology.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.